CDK4 and neoplasm: Although many first generation non-selective CDK4/6 inhibitors failed in clinical development due to toxicity, current CDK4/6 inhibitors in clinical trials are well-tolerated and have demonstrated potential efficacy in a wide variety of tumor types [11–13].